# INO-5401

Source: https://onco.cc/drugs/ino-5401/  
OnCo record `ino-5401` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

INO-5401 is an experimental cancer vaccine from Inovio Pharmaceuticals in phase 2 trials for glioma & glioblastoma, aimed at PSMA.

## Summary

INO-5401 is a cancer vaccine developed by Inovio Pharmaceuticals. Its target is PSMA (the sponsor names WT1, PSMA, hTERT). The sponsor states: A combination of three separate DNA plasmids targeting the Wilms tumour gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT), delivered intramuscularly followed by electroporation with the CELLECTRA device to stimulate an anti-tumour immune response. ClinicalTrials.gov describes the intervention as: INO-5401 is a combination of 3 separate DNA plasmids targeting Wilms tumour gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT) genes. Starting on Day 0 three milligrams (mg) of. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in glioma & glioblastoma. The largest, NCT03491683, plans to enrol 52 participants (actual) with primary completion expected 2026-12-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: vaccine
- Mechanism: A combination of three separate DNA plasmids targeting the Wilms tumour gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT), delivered intramuscularly followed by electroporation with the CELLECTRA device to stimulate an anti-tumour immune response.

## Sources

- ClinicalTrials.gov: trials of INO-5401: https://clinicaltrials.gov/search?intr=INO-5401

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- targets: [PSMA](https://onco.cc/targets/psma/), [WT1](https://onco.cc/targets/wt1/)
- companies: [Inovio Pharmaceuticals](https://onco.cc/companies/inovio/)
- trials: [INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)](https://onco.cc/trials/nct03491683/)

---
JSON: https://onco.cc/api/v1/entities/ino-5401.json